Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. (Q42997068)

12 November 2017

Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. (English)

1 reference

12 November 2017

1 reference

1 reference

1 reference

1 reference

M E Cramp

1

1 reference

12 November 2017

S Rossol

2

1 reference

12 November 2017

S Chokshi

3

1 reference

12 November 2017

P Carucci

4

1 reference

12 November 2017

R Williams

5

1 reference

12 November 2017

N V Naoumov

6

1 reference

12 November 2017

language of work or name

English

0 references

publication date

1 February 2000

1 reference

12 November 2017

1 reference

12 November 2017

118

1 reference

12 November 2017

346-355

1 reference

12 November 2017

2

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970217-4

12 November 2017

1 reference

The treatment of chronic viral hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970217-4

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970217-4

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970217-4

Actions of cytokines on the immune response and viral interactions: an overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970217-4

Hepatitis C viral RNA titers in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970217-4

Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970217-4

Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970217-4

Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970217-4

Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970217-4

Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970217-4

Hepatitis C virus (HCV) specific immune responses in anti-HCV positive patients without hepatitis C viraemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970217-4

T-lymphocyte response to hepatitis C virus in different clinical courses of infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970217-4

Effects of interferon treatment on the antiviral T-cell response in hepatitis C virus genotype 1b- and genotype 2c-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970217-4

Cellular immunity to hepatitis C virus core protein and the response to interferon in patients with chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970217-4

Interferon production in patients infected with HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970217-4

Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970217-4

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970217-4

Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970217-4

Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970217-4

Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970217-4

Hepatitis C: viral kinetics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970217-4

Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970217-4

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970217-4

The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970217-4

Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970217-4

Effects of the ribavirin-interferon alpha combination on cultured peripheral blood mononuclear cells from chronic hepatitis C patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970217-4

Inhibition of immune functions by antiviral drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970217-4

Anergy and exhaustion are independent mechanisms of peripheral T cell tolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970217-4

Viral immune evasion due to persistence of activated T cells without effector function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970217-4

Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970217-4

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0016-5085(00)70217-4

1 reference

12 November 2017

1 reference